FarmaKology -Molecular Agent Designed To Image and Treat Tumors
DNAe is a pioneering molecular diagnostics company developing solutions which enable rapid near-patient, real-time diagnostics. The innovative application of DNAe’s semiconductor technology in LiDiaTM diagnostic products allows us to combine powerful analytical capability and accurate results with speed and simplicity, while performing a range of genomic analyses –from highly parallel separate tests to powerful next generation sequencing (NGS). And in every scenario, it is a complete end-to-end diagnostic solution for a fast actionable result.DNAe’s initial focus is on a diagnostic test for bloodstream infections for use in the management and prevention of sepsis where speed can make the difference between life and death. By accurately and rapidly identifying what infection a patient has, the test will provide the clinician with the actionable information needed to help select the appropriate antibiotics to treat the disease.Founded in 2003, and headquartered in London, UK, DNAe has expanded operations further in 2015 with a clinical diagnostic development and manufacturing site in San Diego, CA. Our company employs over 100 people and we are always on the look out for exceptional talent.
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
Vertex Pharmaceuticals Incorporated and Mammoth Biosciences, a biotech company building the next generation of CRISPR products to cure and detect disease, announced a new partnership to develop in vivo gene-editing therapies for two genetic diseases using Mammoth’s next-generation CRISPR systems.
Novartis receives priority review by US FDA and filing acceptance by EMA for Kymriah® to treat patients with relapsed or refractory follicular lymphoma
Novartis today announced that the US Food and Drug Administration and the European Medicines Agency have accepted the company’s Supplemental Biologics License Application (sBLA) and Type II Variation, respectively, for Kymriah® (tisagenlecleucel) in adult patients with relapsed or refractory (r/r) follicular lymphoma (FL) after two prior lines of treatment. The FDA has also granted priority review to the company’s sBLA for Kymriah in adult patients with r/r FL. Kymriah was previously granted orphan medicinal product designation by the European Commission for FL.
LOVE Pharma Co. , the Company is pleased to announce the debut of its first two products, BLOOM™ and AURALIEF™. Zachary Stadnyk, CEO and Director, stated: “It is with great excitement that we are able to announce the launch of our first two fully-branded products, Bloom and Auralief. We believe these two products within our strong portfolio of intellectual property can quickly command significant market share in the shortest period. We look forward to updating our investors as we progress through the rollout of these first two products and subsequently, the company’s therapeutic and wellness products in a strategic, staggered approach”.
An expert panel on Tuesday voted overwhelmingly to recommend the U.S. Food and Drug Administration authorize the Pfizer Inc and BioNTech SE COVID-19 vaccine for children ages 5 to 11, saying the benefits of the shot outweigh the risks. An authorization for that age group would be would be an important regulatory step toward reaching about 28 million children for inoculation, most of them back in school for in-person learning.
Spend $1 Today, Save up to $2k on Your Next Vacay with Dollar Flight Club.
Research & Study
Science Will Win explores the fascinating science, policy, and humanity which is shaping the future of healthcare and transforming patients’ lives for the better. Hosted by Adam Rutherford, geneticist and Honorary Fellow at University College London, our first miniseries takes listeners on a journey behind the science of gene therapy; the next generation of medicines bringing new possibilities for patients living with rare genetic diseases. At a time when innovative science is achieving the seemingly impossible, we’ll look at gene therapy from every angle, speaking to scientists and experts on the forefront of medical research, as well as the patients and families who are holding new hope in the life-changing potential of gene therapy.